BEDMINSTER, N.J. -- (BUSINESS WIRE) -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced that it will host an Investor and Analyst Event for its research analysts and institutional investors on Friday, December 6 at 8:30 a.m. ET in New York City. Francois Nader, M.D., president and chief executive officer of NPS, will host the event along with other key members of NPS senior management. Expert medical leaders will also be featured speakers at the meeting.
The meeting will primarily focus on the global commercial opportunity for Natpara® in hypoparathyroidism. The company will also provide an update on its lead commercial product Gattex®/Revestive® in adult Short Bowel Syndrome.
A live webcast and replay of the meeting can be accessed by visiting calendar of events page in the Investors section of the NPS website at http://www.npsp.com/calendar. All presentation materials will be made available as part of the webcast. The replay will be available approximately three hours after the event has concluded.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (EU) (teduglutide [rDNA origin]) for injection is approved for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted its marketing application to the U.S. Food and Drug Administration in October 2013. NPS's earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin.